Ian Neeland, MD
Cardiovascular Disease · Cleveland, OHNPI 1285818740
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $231,100 of the $329,260 with a category attached, or 70.2%. 18 manufacturers reported payments, led by Bayer at 49.0% of the total. 2025 is the largest year on record at $125,407, more than ten times the $2,041 reported in 2020. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $1175.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$161K
- Boehringer Ingelheim$110K
- Lilly USA, LLC$27K
- Novo Nordisk$12K
- Eli Lilly$12K
- Nestle Healthcare Nutrition Inc.$4K
- plus $3K from 12 others
Across 37 payments — averaging $6284.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$94K
- Amgen$68K
- Dexcom, Inc.$67K
- Pfizer$4K
What the payments were for
- Consulting fees$61,47119%
- Speaking & faculty fees$231,10070%
- Travel & lodging$32,78310%
- Food & beverage$3,8481%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 106 | $161,249 |
| Boehringer Ingelheim | 92 | $110,020 |
| Lilly USA, LLC | 27 | $26,654 |
| Novo Nordisk | 13 | $12,072 |
| Eli Lilly | 12 | $11,881 |
| Nestle Healthcare Nutrition Inc. | 1 | $4,461 |
| Merck | 2 | $2,016 |
| Boehringer Ingelheim International GmbH | 1 | $183 |
| Boston Scientific | 2 | $164 |
| Novartis | 8 | $148 |
| Sanofi | 1 | $129 |
| Amgen | 5 | $93 |
| Pfizer | 3 | $51 |
| AstraZeneca | 3 | $49 |
| Atricure, Inc. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$329,260 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 199 | $234,338 |
| OzempicSemaglutide | 131 | $168,830 |
| KerendiaFinerenone | 90 | $112,691 |
| MounjaroTirzepatide | 86 | $107,858 |
| TrulicityDulaglutide | 72 | $74,659 |
| Repatha SureclickEvolocumab | 66 | $58,696 |
| EliquisApixaban | 45 | $54,372 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 45 | $47,541 |
| FarxigaDapagliflozin Propanediol | 20 | $26,938 |
| VascepaIcosapent Ethyl | 35 | $25,960 |
| XareltoRivaroxaban | 14 | $10,925 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $10,658 |
| Praluent PenAlirocumab | 11 | $10,027 |
| Icosapent Ethyl | 24 | $8,228 |
| NexletolBempedoic Acid | 11 | $4,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $110,020 | $281,879244 claims |
| Lilly USA, LLCMounjaro, Trulicity | $26,654 | $182,517158 claims |
| Novo NordiskOzempic | $12,072 | $168,830131 claims |
| BayerKerendia | $161,249 | $112,69190 claims |
| PfizerEliquis | $51 | $54,37245 claims |
| AstraZenecaFarxiga | $49 | $26,93820 claims |
| Johnson & JohnsonXarelto | $19 | $10,92514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Cleveland
- Guilherme AttizzaniCleveland$1.3M
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Mazen HannaCleveland$208K
- Brian HoitCleveland$207K
- Steven NissenCleveland$149K
- Daniel CantillonCleveland$140K
- Serge HarbCleveland$134K
- Wael JaberCleveland$124K
- Milind DesaiCleveland$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.